Form 4: Wave Life Sciences Director Exercises Options and Sells Shares Under 10b5-1 Plan

Christian Henry, a director at Wave Life Sciences, executed option exercises and share sales according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 20, 2025, Christian Henry, a director of Wave Life Sciences Ltd., exercised options to acquire 10,500 ordinary shares at a price of $9.13 per share.
• Simultaneously, Henry sold 10,500 ordinary shares at a weighted-average price of $9.769 per share, with individual sales ranging from $9.69 to $9.88.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on November 24, 2024.
• Following these transactions, Henry directly owns 16,115 ordinary shares.
• The exercised share options were fully vested and are set to expire on August 18, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports transactions under a pre-existing trading plan, with no indication of positive or negative implications for the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating no insider information was used.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, ensuring fair market practices.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company director.

Key Dates

Keywords

Wave Life Sciences, Christian Henry, Form 4, Insider Trading, Share Sale, Option Exercise, 10b5-1 Plan, Director